RELAPSE RATE OF TWICE WEEKLY INTERMITTENT CHEMOTHERAPY DURING CONTINUATION PHASE IN THE TREATMENT OF PULMONARY TUBERCULOSIS IN TWO YEARS PERIOD AFTER COMPLETION OF TREATMENT

DOI Web Site 16 References
  • WADA Masako
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • OKUMURA Masao
    Fukujuji Hospital, JATA
  • HOSHINO Hitoshi
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • MITARAI Satoshi
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • OHMORI Masako
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • UCHIMURA Kazuhiro
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • YOSHIYAMA Takashi
    Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (JATA)
  • OGATA Hideo
    Fukujuji Hospital, JATA

Bibliographic Information

Other Title
  • 結核治療における維持期週２回間欠療法の治療終了２年後の再発について
  • ケッカク チリョウ ニ オケル イジキ シュウ 2カイ カンケツ リョウホウ ノ チリョウ シュウリョウ 2ネンゴ ノ サイハツ ニ ツイテ

Search this article

Abstract

[Objective] To evaluate the relapse rate after treatment of a twice weekly intermittent chemotherapy during continuation phase in the patients with pulmonary tuberculosis in two years poriod after completion of chemotherapy.<BR>[Methods] The patients with drug s usceptible pulmonary tuberculosis treated with 2HRZE/4H2R2 under the supervision by the pharmacists or the patients treated with 2HRZE/4HR by self-administration were followed-up for two years after completion of chemotherapy.<BR>[Results] A total number of 135 pulmonary tuberculosis patients were treated with 2HRZE/4H2R2, 3 of 135 discontinued this intermittent treatment, and 11 of 135 completed chemotherapy was excluded from the relapse analysis, 105 out of the remaining 121 were followed-up for more than 6 months. On the other hand 240 patients were treated with 2HRZE/4HR, 37 out of 240 were excluded from the analysis, 147 of the remaining 203 were followed-up for more than 6 months. The relapse rate of this intermittent chemotherapy 1. 89/100 person-year was similar to the relapse rate 1. 86/100 person-year among 147 treated with daily regimen by selfadministration. This difference was not statistically significant (z =0. 36, P=0. 14).<BR>[Conclusion ] As regards relapse rate, this 2HRZE/4H2R2 regimen is effective and useful for the expansion of DOT, and it should be expanded nationally in Japan.

Journal

References(16)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top